Login
$ALT
$1.55 -$0.01 (0.6%) After hours

$ALT SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 Form 4
13 Nov 2026 Form 4: Pisano Wayne, Director

Bought 10,000 shares ($16.4K)

13 Nov 2026 Form 4: Durso Jerome Benedict, Director

Bought 30,700 shares ($49.7K)

13 Nov 2026 Form 4
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Global PERFORMA Phase 3 trial in MASH progressing as planned

10 Nov 2026 SCHEDULE 13G
04 Nov 2026 Form 4: Greenleaf Peter, Director

Granted 160,000 Stock Options (option to buy)

04 Nov 2026 Form 3: Greenleaf Peter, Director

No securities owned

04 Nov 2026 Form 4: Howarth Alex G., Director

Granted 160,000 Stock Options (option to buy)

04 Nov 2026 Form 3: Howarth Alex G., Director

No securities owned

29 Oct 2026 8-K: Creation of a Direct Financial Obligation

On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment t...

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

05 Oct 2026 Form 4: Arbet-Engels Christophe, Chief Medical Officer

Received 37,500 shares by exercise or conversion · Gave up 12,679 shares to cover exercise price or tax ($35K)

05 Oct 2026 Form 4: Weaver Gregory L, Chief Financial Officer

Received 14,475 shares by exercise or conversion · Gave up 4,379 shares to cover exercise price or tax ($12.1K)

02 Oct 2026 Form 4: Menziuso Richard Thomas, Principal Accounting Officer

Granted 84,546 Stock Options (option to buy) · Granted 36,234 Restricted Stock Units

02 Oct 2026 Form 3: Menziuso Richard Thomas, Principal Accounting Officer

No securities owned

29 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2...

17 Sep 2026 Form 4: Richardson Linda M, Chief Commercial Officer

Received 24,000 shares by exercise or conversion · Gave up 6,826 shares to cover exercise price or tax ($22.1K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support